Diagnostic test allergens used for in vivo diagnosis of allergic diseases are at risk: a European Perspective.

L Klimek, H J Hoffmann, H Renz, P Demoly, T Werfel, P M Matricardi, A Muraro, P Schmid-Grendelmeier, V Cardona, N G Papadopoulos

    Research output: Contribution to journalArticlepeer-review


    In the European Union (EU), allergens used for diagnostic tests (TAs) are defined as medicinal products and have to be registered by national authorities. The current situation is not homogeneous. Existing authorizations need to be kept in the market in some EU states, while others need complete new authorizations requiring clinical trials, quality assurance methods, stability studies, and periodic safety update reports. Allergen manufacturers argue that offering a comprehensive panel of TAs may be economically disastrous. Expenses for initiation and maintenance of TA authorizations far exceed their related revenues and manufacturers may be forced to significantly limit their allergen portfolios. The availability of a wide range of high-quality TAs is very important for in vivo diagnoses of IgE-mediated allergies. Increased regulatory demands induce costs that need to be covered by public health organizations or reimbursed by health insurance companies.
    Original languageEnglish
    Issue number10
    Publication statusPublished - Oct 2015


    • European Pharmacopoeia
    • bronchial provocation test
    • conjunctival provocation test
    • nasal provocation test
    • skin test allergens


    Dive into the research topics of 'Diagnostic test allergens used for in vivo diagnosis of allergic diseases are at risk: a European Perspective.'. Together they form a unique fingerprint.

    Cite this